Development and validation of a survival prediction model for patients with advanced non-small cell lung cancer based on LASSO regression
Open Access
- 2 August 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1431150
Abstract
Introduction: Lung cancer remains a significant global health burden, with non-small cell lung cancer (NSCLC) being the predominant subtype. Despite advancements in treatment, the prognosis for patients with advanced NSCLC remains unsatisfactory, underscoring the imperative for precise prognostic assessment models. This study aimed to develop and validate a survival prediction model specifically tailored for patients diagnosed with NSCLC. Methods: A total of 523 patients were randomly divided into a training dataset (n=313) and a validation dataset (n=210). We conducted initial variable selection using three analytical methods: univariate Cox regression, LASSO regression, and random survival forest (RSF) analysis. Multivariate Cox regression was then performed on the variables selected by each method to construct the final predictive models. The optimal model was selected based on the highest bootstrap C-index observed in the validation dataset. Additionally, the predictive performance of the model was evaluated using time-dependent receiver operating characteristic (Time-ROC) curves, calibration plots, and decision curve analysis (DCA). Results: The LASSO regression model, which included N stage, neutrophil-lymphocyte ratio (NLR), D-dimer, neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCC), driver alterations, and first-line treatment, achieved a bootstrap C-index of 0.668 (95% CI: 0.626-0.722) in the validation dataset, the highest among the three models tested. The model demonstrated good discrimination in the validation dataset, with area under the ROC curve (AUC) values of 0.707 (95% CI: 0.633-0.781) for 1-year survival, 0.691 (95% CI: 0.616-0.765) for 2-year survival, and 0.696 (95% CI: 0.611-0.781) for 3-year survival predictions, respectively. Calibration plots indicated good agreement between predicted and observed survival probabilities. Decision curve analysis demonstrated that the model provides clinical benefit at a range of decision thresholds. Conclusion: The LASSO regression model exhibited robust performance in the validation dataset, predicting survival outcomes for patients with advanced NSCLC effectively. This model can assist clinicians in making more informed treatment decisions and provide a valuable tool for patient risk stratification and personalized management.Keywords
This publication has 38 references indexed in Scilit:
- Development and validation of prognostic nomograms for overall survival in patients with locally advanced colorectal cancerAlexandria Engineering Journal, 2023
- Using machine learning to enhance prediction of atrial fibrillation recurrence after catheter ablationJournal of Arrhythmia, 2023
- Expression changes and clinical significance of serum neuron-specific enolase and squamous cell carcinoma antigen in lung cancer patients after radiotherapyClinics, 2023
- SurvSHAP(t): Time-dependent explanations of machine learning survival modelsKnowledge-Based Systems, 2022
- Prognostic evaluation of preoperative serum tumor marker‐negative cases in non‐small cell lung cancer: A retrospective studyCancer Reports, 2022
- Rs2686344 and serum squamous cell carcinoma antigen could predict clinical efficacy of neoadjuvant chemotherapy for cervical cancerCurrent Problems in Cancer, 2021
- Establishment of a Risk Prediction Model for Non-alcoholic Fatty Liver Disease in Type 2 DiabetesDiabetes Therapy, 2020
- Soft tissue sarcoma nomograms and their incorporation into practiceCancer, 2017
- Procoagulant mechanisms in tumour cellsBest Practice & Research Clinical Haematology, 2009
- Regression Models and Life-Tables1992